Abstract Submission Guidelines

Follow the guidelines below to submit an abstract to IKCS: North America.

• All submitters are required to create a free account with Cadmium to access the abstract submitter.

• Important Deadlines
  
• Abstract Submission Deadline (all submissions including LBA placeholder submissions due at this time): AUGUST 7, 2023, AT 11:59 PM PDT

• LBA Final Data Submission Deadline (final data, results, and conclusions for LBA placeholder submissions due at this time): August 31, 2023, at 12:00 PM (Noon) PDT

• Additional instructions will be sent to lead authors to complete their LBA submissions

• Abstract Notifications will be sent to lead authors in September 2023.

• LBA lead authors will receive abstract notifications in Late September 2023.

Abstract Submission Types:

• Regular Abstract (All research types and summaries of new, ongoing, and updated research relating to kidney cancer will be considered)

• Trials in Progress Abstract (All research types that are open, enrolling, ongoing, and have not reached pre-specified endpoints for analysis.)

• Late-breaking Data Submission Abstract (Phase I, II, III, or IV trials and original, high-impact research that could impact practice and standard of care)

• Case Report (A report of the diagnosis, treatment, and follow up of an individual patient)

Abstract Sections:

• Abstract Title: The title should objectively describe the study and should not include proprietary drug names.

• Abstract Text: The abstract text should be no more than 300 words including the title and abstract body. Word count does not apply towards spaces, authors, and affiliations. All abstracts should be structured into four sections: Background, Methods, Results, Conclusions

• Optional Abstract Graph, Illustration, or Table: One brief graph, illustration, or table is permitted.

• Authors: The maximum number of authors permitted is 20.
• Pharmaceutical industry authors are allowed to present abstracts in non-CME sessions (Poster Sessions). If an abstract is selected for presentation in a CME-session, and the presenter has financial relationships with ACCME-defined ineligible companies, an alternate presenter must be identified. A non-named author can present a poster if written permission is provided by the lead author to [email protected].

• Conflict of Interest Disclosure: Presenting authors must submit a Conflict of Interest disclosure identifying financial relationships with ACCME-defined ineligible companies. Co-authors do not need to submit a COI Disclosure.

Abstract Policies:

• Confidentiality Policy: Abstracts are confidential at the time of submission. KCA will release full abstracts on the meeting platform website November 7, 2023 at 16:00 BST leading up to the meeting. Meeting registration is required to access the abstracts.
• Abstract Presentation Ownership: Abstract Presentations (PPT slides and Posters) are owned by the author.
• KCJ Open Access Policy
• Permissions Policy
• Abstract Presentation Ownership: Abstract Presentations (PPT slides and Posters) are owned by the author and will not be published/printed by KCA/KCJ.

Abstract Submission Categories

Abstracts in the following categories will be considered for presentation:

• Basic Science
• Disparities in Cancer, Care and Access
• Diagnostics
• Financial Toxicity – Care Delivery/Health Outcomes
• Imaging
• Patient-reported Outcomes
• Post-treatment Surveillance
• Prevention and Screening
• Quality of Care and Quality Improvement
• Real-World Evidence
• Survivorship
• Treatment Toxicities and Symptom Management
• Therapeutics (Systemic- Radiation Therapy, Ablation, Surgery, Interventional Radiology, Urology, Medical Oncology, etc.)
• Therapeutics (Local- Primary and Metastatis)
• Tumor Biology, Biomarkers, and Pathology
• Other

Abstracts submitted in this category are Phase I-IV trials, or original research that could impact practice and standard of care. LBA Abstracts should be studies where results and conclusions are not yet available by the August 7 deadline, but will be available by the August 31, 2023 12:00 PM (Noon) PDT deadline.

Abstracts submitted in this category must have a placeholder submission (all components except for Results and Conclusions sections) received by the August 7, 2023 11:59 PM PDT abstract submission deadline.

Lead authors will receive separate instructions to complete LBA placeholder submissions by the August 31, 2023 LBA deadline.

Abstracts submitted in this category are ongoing and should not include data, results, nor conclusions.

TPS abstracts are open, enrolling, or ongoing and have not reached any protocol-specific endpoints for analysis, and consequently will only require the completion of the Background and Methods sections.

Abstracts in all phases of clinical research (I, II, III, IV) may be submitted.

TPS Abstracts, if accepted, are eligible for Poster Presentation. TPS abstracts are not eligible for Oral Presentation.

Abstract Review and Selection Process

Abstracts will be reviewed by the IKCS: North America Scientific Planning Committee. Abstract notifications will be sent to lead authors in early September 2023.

IKCS: North Merit Awards

Merit Award Eligibility Requirements:

• Submit an abstract  
• Must be enrolled and in good standing in an oncology or urology training program, fellowship, or post-doctoral researcher position.

Selection Process:

The IKCS Scientific Planning Committee will select four recipients to receive a merit award for the best original submissions.

Winners

All four winners will receive a complimentary registration to IKCS 2023 North America, be recognized in the program booklet and on stage, and provided a speaking slot during the oral abstract session.

Abstract Presenter Guidelines

All accepted abstracts and lead authors are requested to present in-person at IKCS: North America. Accepted abstracts will be displayed at the live meeting and electronic versions will be available online for post-meeting on-demand access.

All Abstract Presenters must register for the conference.

Oral Abstract Presenter Guidelines

• Presentation Format: Oral Abstract Presenters should prepare a 7-minute PPT presentation
• Slide Upload Deadline: PPT slides are due in the presenter portal by October 20, 2023. We will try our best to process late files, however, files received after this date cannot be guaranteed inclusion in the conference platform.
• Download the PPT slide template
• Conflict of Interest Disclosure: Oral Abstract Presentations must include in a COI Disclosure slide
• Withdrawal Deadline: All withdrawal requests must be sent in writing from the first author to [email protected] by October 13, 2023. Requests received after this date cannot be guaranteed removal from the program.
• Corresponding Poster: Oral Abstract presenters must also prepare a poster presentation to accompany their oral presentation.

Poster Presenter Guidelines

• Poster Presenters should prepare a PDF and printed poster. Attendees will have the opportunity to visit posters in-person onsite and view electronic versions online.
• ePoster Deadline: Presenters should upload a PDF poster to the Speaker Portal by October 30, 2023. We will try our best to process late files, however, files received after this date cannot be guaranteed inclusion in the conference platform.
• Printed Posters: Poster Presenters should bring a printed poster onsite to hang on an assigned poster board for the duration of the meeting.
• Size: You are provided a 4’x 4′ board space. Printed posters should not exceed 42 inches by 42 inches (106 cm by 106 cm). Poster hanging materials will be provided onsite.
• Printing: Poster Presenters should arrange their own poster printing and carry their poster onsite. If a Poster Presenter is unable to attend in-person, they should arrange for a colleague to carry the poster onsite or contact KCA at [email protected] to obtain shipping information to send the poster to the meeting.
• KCA is not responsible for costs associated with printing and shipping posters.
• Template: No specific Poster Template is required.
• Withdrawal Deadline: All withdrawal requests must be sent in writing from the first author to [email protected] by October 13, 2023. Requests received after this date cannot be guaranteed removal from the program.

Abstract titles will be released on the meeting platform early October 2023.

Poster Presentations will become available beginning November 7, 2023. PDF versions of presentation slides will become available during the specific session for the presentation.

Abstract Submission Closed

Please contact [email protected].